Ameriprise’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$56.2M Buy
702,031
+27,687
+4% +$2.28M 0.01% 815
2025
Q4
$57.2M Buy
674,344
+63,217
+10% +$5.19M 0.01% 804
2025
Q3
$47.3M Sell
611,127
-93,387
-13% -$7.3M 0.01% 917
2025
Q2
$54.9M Sell
704,514
-50,523
-7% -$3.77M 0.01% 807
2025
Q1
$54.6M Sell
755,037
-2,062
-0.3% -$148K 0.01% 798
2024
Q4
$56.1M Sell
757,099
-1,332,490
-64% -$93.3M 0.01% 781
2024
Q3
$138M Sell
2,089,589
-1,113,141
-35% -$80.9M 0.04% 440
2024
Q2
$296M Buy
3,202,730
+747,771
+30% +$66.2M 0.08% 254
2024
Q1
$236M Buy
2,454,959
+633,858
+35% +$53.2M 0.06% 303
2023
Q4
$141M Buy
1,821,101
+136,290
+8% +$9.48M 0.04% 410
2023
Q3
$115M Sell
1,684,811
-418,967
-20% -$33.7M 0.04% 438
2023
Q2
$198M Sell
2,103,778
-96,130
-4% -$8.36M 0.06% 309
2023
Q1
$182M Buy
2,199,908
+21,090
+1% +$1.66M 0.06% 319
2022
Q4
$163M Sell
2,178,818
-1,237,435
-36% -$95.4M 0.06% 348
2022
Q3
$283M Sell
3,416,253
-426,967
-11% -$41.1M 0.1% 213
2022
Q2
$365M Buy
3,843,220
+873,155
+29% +$90.4M 0.13% 173
2022
Q1
$348M Buy
2,970,065
+214,484
+8% +$24.1M 0.1% 217
2021
Q4
$355M Sell
2,755,581
-551,182
-17% -$64.3M 0.1% 215
2021
Q3
$374M Sell
3,306,763
-1,757,652
-35% -$201M 0.12% 188
2021
Q2
$524M Buy
5,064,415
+33,525
+0.7% +$3.16M 0.16% 137
2021
Q1
$421M Buy
5,030,890
+1,381,907
+38% +$117M 0.14% 159
2020
Q4
$333M Sell
3,648,983
-174,265
-5% -$14.5M 0.12% 184
2020
Q3
$305M Sell
3,823,248
-78,747
-2% -$6.14M 0.12% 179
2020
Q2
$270M Buy
3,901,995
+418,782
+12% +$29.8M 0.12% 191
2020
Q1
$219M Sell
3,483,213
-1,108,929
-24% -$80M 0.11% 188
2019
Q4
$357M Sell
4,592,142
-455,433
-9% -$35.6M 0.15% 150
2019
Q3
$370M Sell
5,047,575
-584,865
-10% -$41.1M 0.17% 126
2019
Q2
$347M Sell
5,632,440
-115,677
-2% -$6.99M 0.16% 134
2019
Q1
$367M Sell
5,748,117
-807,336
-12% -$46.1M 0.17% 125
2018
Q4
$334M Sell
6,555,453
-173,178
-3% -$8.76M 0.17% 130
2018
Q3
$390M Sell
6,728,631
-278,622
-4% -$13.6M 0.14% 171
2018
Q2
$340M Sell
7,007,253
-1,726,065
-20% -$80.6M 0.15% 143
2018
Q1
$406M Sell
8,733,318
-2,652,780
-23% -$115M 0.18% 120
2017
Q4
$428M Sell
11,386,098
-1,308,327
-10% -$48M 0.2% 110
2017
Q3
$463M Sell
12,694,425
-384,636
-3% -$14.7M 0.22% 100
2017
Q2
$515M Sell
13,079,061
-4,133,316
-24% -$151M 0.26% 83
2017
Q1
$540M Buy
17,212,377
+2,550,504
+17% +$79.9M 0.28% 77
2016
Q4
$458M Buy
14,661,873
+1,700,064
+13% +$55.1M 0.25% 82
2016
Q3
$521M Buy
12,961,809
+199,881
+2% +$7.53M 0.29% 72
2016
Q2
$424M Buy
12,761,928
+4,897,701
+62% +$168M 0.25% 84
2016
Q1
$231M Buy
7,864,227
+6,931,194
+743% +$191M 0.14% 160
2015
Q4
$24.3M Sell
933,033
-53,931
-5% -$1.4M 0.01% 825
2015
Q3
$23.2M Buy
986,964
+665,778
+207% +$16.1M 0.01% 840
2015
Q2
$7.63M Buy
321,186
+44,850
+16% +$1.01M ﹤0.01% 1815
2015
Q1
$6.53M Sell
276,336
-315,270
-53% -$7.07M ﹤0.01% 1920
2014
Q4
$12.5M Buy
591,606
+233,652
+65% +$4.69M 0.01% 1315
2014
Q3
$6.09M Buy
357,954
+136,812
+62% +$2.16M ﹤0.01% 1893
2014
Q2
$3.16M Sell
221,142
-1,686
-0.8% -$22.9K ﹤0.01% 2326
2014
Q1
$2.75M Sell
222,828
-101,628
-31% -$1.17M ﹤0.01% 2354
2013
Q4
$3.56M Sell
324,456
-28,800
-8% -$325K ﹤0.01% 2200
2013
Q3
$4.1M Sell
353,256
-28,472,250
-99% -$333M ﹤0.01% 2071
2013
Q2
$323M Buy
+28,825,506
New +$341M 0.22% 98

Other funds holding EW

Ameriprise's EW Position: Q1 2026 in Review

Ameriprise increased its Edwards Lifesciences (EW) stake by 4.1% in Q1 2026, buying an estimated $2.28M and bringing the position to 702,031 shares worth $56.2M. The position accounts for 0.01% of the portfolio, ranked #815.

Ameriprise first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $540M in Q1 2017. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Ameriprise held 702,031 shares of Edwards Lifesciences worth $56.2M as of Q1 2026.
  • Ameriprise bought 27,687 Edwards Lifesciences shares in Q1 2026, an estimated $2.28M.
  • Edwards Lifesciences made up 0.01% of Ameriprise's portfolio in Q1 2026, its #815 holding.
  • Ameriprise first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
  • Ameriprise's Edwards Lifesciences position peaked at $540M in Q1 2017.
  • 1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.